VI. Carcinoma of the ovary

VI. Carcinoma of the ovary

238 VI. OVARY CARCINOMAOF THE OVARY ANATOMY Primary Site. Ovaries are a pair of solid bodies, flattened ovoids 2.0 to 4.0 cm in diameter, that are c...

1MB Sizes 3 Downloads 87 Views

238 VI.

OVARY CARCINOMAOF THE OVARY

ANATOMY Primary Site. Ovaries are a pair of solid bodies, flattened ovoids 2.0 to 4.0 cm in diameter, that are connected by a peritoneal fold to the broad ligament and by the infundibulo-pelvic ligament to the lateral wall of the pelvis. The peritoneum, including the omentum, the pelvic and abdominal viscera, and the diaphragm are common sites for seeding. The lymphatic drainage occurs by the utero-ovarian and round Nodal Stations. ligament trunks and an external iliac accessory route into the following regional nodes: External iliac, common iliac, hypogastric, lateral sacral, and para-aortic nodes, and rarely, to inguinal nodes. Metastatic Sites. Liver vement also occurs.

metastases

are common. Pulmonary

RUL.RSFOR STAGING OF PIUWARYCARcm

and pleural

invol-

OF TRE OVARY

Only rarely is it possible to come to a final diagnosis of ovarian carcinoma by inspection or palpation or by any of the other methods recommended for clinical staging of carcinoma of the uterus and vagina. Therefore, the Committee on Gynecology Oncology of FIG0 recommends that the clinical staging of primary carcinoma of the ovary should be based on findings by laparascopy or laparotomy, as well as on the usual clinical examination and roentgen studies. of ovarian masses, as well as hysterectomy Thus, laparotomy and resection form the basis for staging. Biopsies of all suspicious sites, such as the omentum, mesentery, liver, diaphragm, and pelvic and para-aortic nodes, are required. The final histologic findings after surgery able) are to be considered in the staging.

(and cytologic

ones when avail-

Clinical studies, if carcinoma of the ovary is diagnosed, radiography of chest. CT may be helpful in both initial follow-up of tumours.

include routine staging and

DRFINITIONS OFTRRSTAGRS IN l%IHARYcARc~oFTREovARY (Correlations Staging exploration

is

Stage I Stage Ia

of the FIGO, UICC and AJCC nomenclatures) based on (see above).

findings

at

clinical

examination

Growth limited to the ovaries Growth limited to one ovary; no ascites No tumour on the external surface; capsule intact

and

surgical

OVARY

Stage Ib Stage Ic*

Stage

II

239

Growth limited to both ovaries; no ascites No tumour on the external surfaces; capsules intact Tumour either Stage Ia or Ib, but with tumour on surface of one or both ovaries; or with capsule ruptured; or with ascites present containing malignant cells or with positive peritoneal washings Growth involving one or both ovaries with pelvic extension

Stage IIa Stage IIb

Extension Extension

Stage IIc*

Tumour either Stage IIa or IIb, but with tumour on surface of one or both ovaries; or with capsule(s) ruptured; or with ascites present containing malignant cells or with positive peritoneal washings

Stage

III

Stage IIIa

Stage 1116

Stage IIIc Stage

IV

and/or metastases to the uterus to other pelvic tissues

and/or tubes

Tumour involvning one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver metastasis equals Stage III true pelvis but with Tumour is limited to the histologically proven malignant extension to small bowel or omentum Tumour grossly limited to the true pelvis with negative nodes but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces Tumour involving one or both ovaries with histologically confirmed implants of abdominal peritoneal surfaces none exceeding 2 cm in diameter. Nodes are negative Abdominal implants greater than 2 positive retroperitoneal or inguinal one or both Growth involving metastases. If pleural effusion is positive cytology to allot a case to Parenchymal liver

cm in diameter and/or nodes ovaries with distant present there must be Stage IV

equals Stage IV criteria * In order to evaluate the impact prognosis of the different allotting case to Stage Ic or IIc it would be of value to know: If the source of malignant cells detected was 1) 2) If a) b)

peritoneal washings or ascites rupture of the capsule was spontaneous or caused by the surgeon

metastasis

for

240

OVARY

HISTOPATEOILIGY

Ovarian carcinoma is a common malignant tumour. It cannot be regarded as an entity. Therapeutic statistics on ovarian cancer are of limited value if attention is not paid to the histological type of the growth. ovarian tumours" The WHO has published a "Histological typing of (International Histological Classification of Tumours, No. 9, 1973) which certainly will help to understand the pathology and behaviour of ovarian neoplasms. The histo-pathological classification of epithelial tumours adopted by the WHOcorresponds in principle with that proposed by FIGO. It should be noted that cases of germ cell tumours, hormonal producing neoplasms, and metastatic carcinomas should be excluded from therapeutic statistics on ovarian epithelial tumours. HIsTo~ICALcLcLssIl?ICATIoNoFTEEcomoN OVARY

1.

Serous

a) b)

c) 2.

3.

4.

PRIHAKY

EPITEELIAL

TamuRs

OF TEIR

cystanas

Serous benign cystadenomas Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities, but with no infiltrative destructive growth (boderline cases; low potential malignancy) Serous cystadenocarcinomas

Mutinous

cystomas

a) b)

Mutinous benign cystadenomas Mutinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities ,,but with no infiltrative destructive growth (borderline cases; low potential malignancy)

c)

Mutinous

Endaaetrioid

cystadenocarcinomas (similar benign cysts

tumours

to adenocarcinoma in the endometrium)

a)

Endometrioid

b)

Endometrioid tumours with proliferating activity of the epithelial cells and nuclear abnormalities, but with no infiltrative destructive growth (borderline cases; low potential malignancy)

c)

Endometrioid

Clear

cell

tmours

adenocarcinomas (mesonephroid

tumours)

a)

Benign mesonephroid tumours

b)

Mesonephroid tumours with proliferating activity of the epithelial but with no infiltrative destructive cells and nuclear abnormalities, growth (borderline cases; low potential malignancy) Mesonephroid cystadenocarcinomas

c)

OVARY

241

Undifferentiated carcinoma A malignant tumour of epithelial structure that is too poorly differentiated to be placed in any of the groups 1 - 4 or 6. Mixed epithelial tumours Tumours composed of a mixture of two or more of the malignant groups lc, 2c, 3c or 4c described above and where none of them is predominant. Thus, a case should be listed as "mixed epithelial tumour" only if it is not possible to decide which is the predominant structure. The pathologist should always try to find out which is structure and classify the case according to that element. No histology

the

leading

or unclassifiable

Cases where explorative surgery has shown that obvious ovarian epithelial malignant tumour is present, but where no biopsy has been taken, or where the specimen is unclassifiable because' of, for instance, necrosis. RliLJfS RELATING TO STATIMENTS 1.

A statement should preferably comprise at least 10 examined cases per year, but reports of fewer cases will be accepted.

2.

Statements should include all cases of primary common epithelial tumours considered as ovarian carcinoma. The very rare cases where it has not been possible to decide whether the origin of the growth is in the ovary or in the uterine corpus should be included in the statistics on carcinoma of the corpus as well as in the statistics on ovarian cancer (see also Rules for corpus, 2.). Cases of low potential malignancy, often called borderline tumours, should be reported.

3.

Cases where no biopsy has been taken, but where explorative surgery has shown that obvious malignant ovarian tumour is present should be reported.

4.

Cases should be histologically grouped and staged according to the systems adopted by FIG0 (see above). with a view to treatment All patients examined at the institution should be included as well as patients referred for treatment after primary surgery at another hospital. Because of the wide variation in the organisation of cancer services, it is impossible to establish rules for all details of exclusion or collaborators are inclusion of cases. If in doubt or uncertain, requested to apply to the Editorial Office.

5.

242 OVARY 6. The following categories of cases should not be included: a) Patients referred for diagnosis only. b) Recurrent cases of carcinoma of the ovary. c) Cases diagnosed at autopsy. d) Cases with a metastatic ovarian carcinoma from either a genital or extra-genital site. cell e) Non-epithelial tumours, such as dysgerminoma, granulosa tumours, and germ cell tumours. f> Cases of anaplastic inoperable widespread malignant tumours where the gynecologist could not decide the origin of the growth. Such cases should be classified as carcinoma abdominis.

OVARY

243

SIIEHARYAND~ To the Editorial Office of Annual Report 42,786 cases of obviously malignant cases of. epithelial ovarian cancers and 3,181 cases of low potential malignancy were reported to volumes 15 through 21, that is cases treated from 1958 onwards to 1986 inclusive. Table C.1 gives a summary of the treatment results for obviously malignant ovarian cancer given as crude S-year survival rate stage by stage and as a total for each year. The calculated S-year results improved slightly in the end of 1960's but are thereafter essentially unchanged. Please observe that the results for volume 21 are given both as direct crude S-year survival and as actuarial survival. Table C.1

Ovarian cancer. Obviously malignant cases. Five-year crude survival rate by stage. Cases reported to volumes 15 - 21.

Vol.

No. of cases

Year

Stage Ia

Ib

Ic

15

1958-62

2,320

60.7

16

1963-68

4,588

66.7

51.9

17 18

1969-72 1973-75

4,892 5,268

72.0 69.7

62.5 63.9

19 20

1976-78 1979-81

6,724 8,082

72.3 76.6

56.1 67.7

21

1982-86 10,912

IIa

42.0 (Ib IIa)

survival

IIbtc

III

IV

%

31.6(IIb)

6.9

2.6

26.8

49.7

38.0

8.6

5.0

27.3

57.4 50.3

52.2 51.8

37.5 42.4

10.8 13.3

4.6 4.1

30.1 30.5

58.1 59.6

47.7 51.1

42.1 43.5

13.5 17.4

4.5 4.7

29.8 30.9

53.8*

22.75; 8.0*

82.3* 74.9* 67.7" 60.6*

42,786 * S-year actuarial

Total

31.9(35*)

Table C.11 gives a summary of ovarian cancer cases of a low potential malignancy reported from volume 15 through volume 21. The figures speak for an improvement in results from the beginning of 1970's. Thereafter the results are unchanged.

Table C.11

Ovarian cancer. Cases of low potential malignancy. Five-year crude survival rate. Cases reported to volumes 15 - 21.

Vol

Year

No. of cases

Total Stage Ia - IV %

15

1958-62

451

67.2

16 17

1963-68 1969-72

385 403

73.8 73.4

18

1973-75

304

78.6

19 20

1976-78 1979-81

371 542

78.7 77.5

21

1982-86

725

78.6 (89.1)*

3,181 * 5-year actuarial

survival

In Table C.111, the cases of carcinoma of the ovary reported to volume 21 are presented with 3 and 5-year actuarial survival by stage. Please, observe that this table includes obviously malignant cases as well as cases of low potential malignancy. In contrast with the case in previous volumes these data are given as actuarial survival and therefore not directly comparable with the crude survival data given earlier.

OVARY 245 Table CL111

Stage

Carcinoma of the ovary. Patients and five-year actuarial survival obviously malignant cases as well malignancy.)

Patients

No.

treated a

No.

3-year survival %

S-year survival No. % 1134

79.3

403 250

57.0

I II

3073 1469

26.5 12.7

2406 933

85.5 69.0

III IIIa

2342 365

20.2

724 193

33.7

IIIb

580

229

IIIC

1961

5.0 16.9

57.6 44.1

491

IV

1740

15.0

56

0.5

11596

100.0

Incomplete data TOTAL

treated in 1982-86. Three rate by stage.(Includes as cases of low potential

82

22.5 49.0

28.1

87 136

32.9 18.5

219

14.3

74

8.4

5219

49.8

2173

40.9

3.2

Table C.IV gives information about the three-year result. 3.3% of the were lost sight of and 2.0% had died from intercurrent disease.

Table C.IV

Carcinoma of the ovary. year result.

Patients

treated

in 1982-86. Three-

3-year result

No. of

%

patients -,

Alive

5,551

47.9

Died of carcinoma of the ovary Lost sight of

5,431 385

46.8 3.3

229 11,596

2.0 100.0

Died from intercurrent TOTAL

disease

cases

246 OVARY The mean age by stage and histological class is given in Table C.V. An increase in mean age by stage is seen by and large for all histological classes. Table C.V

Carcinoma of the ovary. Patients treated age by stage and histological class.

Stage

Histological

in 1982-1986. Mean

class

Serous

Mutinous

Endometrioid

Clear cell

Undiff. & unspecified

Ia

56.3

50.5

55.9

55.2

55.8

Ib Ic

52.8 56.2

56.5 53.5

53.8

54.5

55.7

53.8

52.2

54.1

IIa

56.9

52.6

56.1

53.8

57.4

IIb

57.0

57.8

55.1

61.4

58.2

IIC III

54.6

55.4 61.0

57.2 59.0

59.2 58.5

58.0

55.7

56.4

55.3

61.8 58.6

55.8

56.9

55.1

59.9

59.8

57.7 59.9

57.6

58.0

58.7

59.9

74.2

58.2 60.3

59.2 62.0

59.2 50.0

61.0 66.9

48.1

50.2

56.9

51.8

IIIa IIIb IIIC IV No stage Low potential malignancy

58.6 53.8

The histogram in Fig. C.l gives the distribution malignant cases and in Fig. C.2 for potentially

by age for obviously malignant tumours.

OVARY

247

The age distribution profile for obviously malignant carcinoma of the ovary is presented in Fig.C.l and for cases of low potential malignancy in Fig.C.2. 74.1% of the obviously malignant cases belong to ages 50 years or more compared to 50.9% for the low potential malignancy cases. Only 8.7% of the obviously malignant cases were younger than 40 years compared to 31.8% of the low potential malignancy cases. Fig C.l Obviously malignant carcinoma of the ovary. Age distribution 30

Percentage of patients

20

10

o-29

Fig.

30-

40-

6s

Carcinoma of the ovary. Casesof low potential Age distribution

c.2 30 ’

60-

70 + Age

malignancy.

Percentage of patients

20 -

o-29

30-

40-

60-

60-

701- Age

248 OVARY TABLE C-VI

Histological class (see p.240 for defin.) Obviously

Carcinoma of the ovary, Stages I-IV. Obviously malignat cases and cases of low potential malignancy, examined in the years 1982-1986, incl., at 100 institutions. Stage distribution and 3 and 5-year actuarial survival rate. Total No. exam

malignant

Stage Ia

Stage Ib

Stage Ic

No. survival exam 3-yr 5-yr % %

No. survival exam 3-yr 5-yr % %

No. survival exam 3-yr 5-yr % %

cases:

IC

5 654

431

87.6

81.5

163

87.7

79.3

318

77.4

66.9

2c

1 256

401

92.2

88.2

30

60.0

55.4

186 81.8

75.2

3c

1 800

323

85.4

82.2

64

84.3

75.6

176

84.8

71.0

621

176

79.1

75.3

4

86

62.9

56.0

1 581

96

80.3

74.6

22

86.4

67.3

73

69.3

58.0

1 427

86.8

82.3

283

83.9

74.9

839

77.8

67.7

4c Undiff. and unspecified TOTAL

10 912"

Cases of low potential

malignancy:

Serous

379

165 93.6

90.8

68

96.9

92.9

21 100.0 100.0

Mutinous Other

317 29

209 9

96.0

92.5

14 1

92.9

85.1

38 2

91.1

91.1

TOTAL

725*

383

95.0

91.9

83 -

96.2

91.6

63 -

94.7

94.7

* Includes

non-staged

patients

The three and five-year actuarial survival by histological class and stage is given in Table C.VI for obviously malignant cases and for low potential malignancy cases.

OVARY

249

Stage

IIa

Stages

IIb

t IIc

Stage

III

Stage

No. exam

survival 3-yr 5-yr % %

No. exam

survival 3-yr 5-yr % %

No. exam

survival 3-yr 5-yr % %

No. survival exam 3-yr 5-yr % %

132

75.5

58.1

485

67.5

55.0

3 123

36.1

24.5

36

63.0

54.0

105

62.9

54.9

369

27.8

103

83.5

68.6

253

71.2

60.4

692

17

62.9

62.9

104

64.3

54.1

37

62.9

52.2

137

52.7

325

74.5

60.6

1084

10

16.8

9.3

21.2

129 16.4

8.6

34.5

24.1

189

9.8

6.0

179

17.7

14.0

55

a.5

4.3

36.8

807

26.4

17.0

409

8.9

6.3

65.7

53.8

5 170

33.1

22.7

1 784 13.9

8.0

32

96.9

93.5

78

91.8

90.3

3

3

15

100.0

100.0

32

70.3

51.3

6

0

1

16

18.8

la.8

0

13

48 -

126

76.6

70.9

9

97.9

95.6

1 002

IV

250 OVARY The study of the actuarial survival by year after treatment and by stage (life table analysis) for serous ovarian carcinomas is presented in Fig. C.3 and C.4. Fig.

Obviously malignant 8610~scarcinoma of the ovary, 1982-1986. Life table presentation by stage I-II.

C.3

-..-. -.-. --..-_ ............. . ...-..

stage I stage la Stage lb

Stage Ic stege II stage Ile Stege Ilb Stage llc

60-I

4020 0

I 1

0

I 2

slwvhral

Fig.

c-4

r 5

I 4

I 3

the

&eaml

Obvioudy malignant serow carcinoma of the ovary, 1982-1986. Life table presentation by stage III-IV.

stage Ill

-Stage llla . . . . Stage ltlb -.-. Stage lllc -Stege IV

0

1

2

3

5

4 survivd

the

(yead

OVARY 251 The actuarial survival by year after treatment and by histological grade for Stage Ia cases respectively Stage IIIb cases is presented in Fig. C.5 and C.6. Fig.

Obviously malignant seroue carcinoma ofthe ovary Stage Ia, 1982-1986. Life table presentation by histological grade.

C.5

Cumulative proportion surviving % 100~

Grade 1 s-s-.... Grade 2 - a

-.

Grade 3

*-..

--..__e - - -_ ---.... - -------. ...*__ ,“- -...., --

--

8060-

00 0

Fig.

C.6

Obvioualy

2

1

malignant

3

4

serous carcinoma

ofthe

Stage IQ 1982-1986. Life table presentation histological grade.

5

ovary

by

Grade 1 .----se. Grade 2

Cumulative proportion surviving %

-

-

Grade3

100

80 60

0

1

2

3

4

5

Survival time (yews)

252 OVARY Three and five-year actuarial survival rate by mode of Ia, Ib and Ic is given in Table C.VII. The choice of these early stages is probably guided by knowledge of which should explain many of the differences in treatment Table C.VII

Carcinoma of the ovary. Patients and five-year actuarial survival in Stages Ia, Ib and Ic.

Stage

Mode

of

676

Ib

90

Ic Not substaged

561

treated in 1982-1986. Three rate by mode of treatment

Surgery combined with No. treated

93.4

233

89.6

393

77 93.2

41

89.6

84

110

80

83.5

28

73.8

202

38

28

88.6

13

79.2

9

Surgery combined with chemotherapy Ia Ib

486 107

Ic 403 Not substaged 23

in Stage given in factors

treatment

Surgery alone Alive at No. kreated 3 years 5 years No. % No. % Ia

treatment treatment predicting results.

Alive

radioth.

at

3 years No. %

5 years No. %

325 90.5

157

88.1

90.3

38

84.9

154 80.6

84

76.3

72

9

2

Surgery combined with chemotherapy and radiotherapy

381 85.1 85 83.7

190 38

81.6 75.0

181 83

135 77.9 59 77.1

86 68.9 37 65.0

287

78.7

114

68.8

186

137 75.0

67

19 76.3

5

70.2

1

1

0

61.2

OVARY 253 Carcinoma of the ovary, low potential -malignancy cases, Stage I - IV are presented in Table C.VIII with 3 and S-year actuarial survival by mode of treatment. Table C.VIII

Carcinoma of the ovary. Patients treated in 1982-86. 747 cases of low potential malignancy, Stage I-IV. Three and fiveyear actuarial survival rate by mode of treatment.

Mode of treatment

No. treated

Alive 3 years No.

%

at 5 years No.

%

Surgery alone

381

314

94.7

146

92.0

Primary surgery t radiotherapy

117

92

92.7

43

89.6

Primary surgery t chemotherapy

197

154

86.1

69

80.7

52

45

94.1

26

94.1

6

2

Primary surgery t comb. rad. t chemotherapy Other

1

Table C.IX gives the 3 and S-year actuarial survival for carcinoma of the ovary Stage Ic and IIc by basis for diagnosis. It would seem that tumours ruptured by the surgeon have a more favourable prognosis than those ruptured spontaneously. Table C.IX

Carcinoma of the ovary, Stage Ic and 11~. Three and five-year actuarial survival rate by basis for the diagnosis.

Criteria

Stage No. treated

Peritoneal

Survival 3 years No. %

5 years No. %

85.2 76.9 71.0

9 71.0 8 67.9 11 61.8

91.4

42

washings

27

Ascites Spontaneous rupture

58 50

21 42 33

95

82

2 4

1 4

Rupture caused by the surgeon Combination of the above mentioned Tumour on the surface

Stage

Ic

1 1

79.7

No. treated

IIc Survival 3 years No. %

5 years No. %

7 30 19

5 15 57.5 12 67.4

1 4 42.5

43

31

1

1

1

0

76.1

8

60.7

13 59.4

0

254 OVARY the Survival by completeness of surgery in Stage III cases. Fig. C.7 gives actuarial survival rate by year after treatment for Stage IIIa cases. The 5-year actuarial survival for cases with growth completely removed was 78.8 per cent compared to 21.6 per cent for cases with residual tumour greater than 2 cm. The corresponding figures for Stage IIIb cases was 54.4 per cent compared to 23.8 per cent (Fig. C.8) and for Stage 111~ 43.3 per cent compared to 11.4 per cent (Fig. C.9).

Fig.

Obviouslymalignant serou~ carcinoma of the ovary

C.7

Stage IDa, lQQ2- 1988. Life table analysis by completeness of surgery. -1 .__._._. 2

cumullrlhreproportion

--

swvMng%

\ 60604040 -I 20

\

3

-*.**... *.-_--.. -=... \\ ---.... -... -....*--...... \ ------.......... \. . . . . .

4

Code for completeness of surgery: l- Growth completely removed 2- Growth incompletely excised, no residual implant greater than 2 cm 3- Growth incompletely excised, residual lesion(s) greater than 2 cm

. . ----

OVAKY Fig.

C.8

Obviously malignant wrous carcinoma of the ovary Stage II& 1982-1986. Life table analysis by completeness of surgery. -1

c . . . . .. 2 -3

Cumulative proportion surviving %

80-

\

6040200 0

I 1

I 2

I 4

I 3 Suwival

Fig.

f 5

time (years1

Obviously malignant serous carcinoma of the ovary &age I& 1982-1986. Life table analysis by completeness of surgery.

C.9

-1 . . . .. . . 2 -3

Cumulative proportion surviving %

100 80 60

L- - -- --0 i

0

I

1

I 2

I 4

I 3 Survival

time M2arsI

r 5

255

OVARY

257

UMBINKDTABIJBFORTKEINDlSADUALINSTITiJTIONS The tabular forms to be used when reporting available on application to the Editorial Radiumhemmet, S-104 01 Stockholm, Sweden.

on carcinoma of the ovary are Office of the Annual Report,

For the definitions of classification by site and staging of carcinoma of the ovary and of the histological classification of the common primary epithelial tumours of the ovary the reader is referred to pp. 238-241. The rules relating to statements to be furnished by collaborators are given on pp. 241-242. Notes

on the

presentation

of

the

material.

Information concerning cases of carcinoma of the ovary examined in the years 1982-1986 has been furnished by 99 of the 147 collaborators. Table C.Xa reviews the three and five-year actuarial survival carcinoma reported by the different institutions (Stages I-IV). Table C.Xb gives the distribution by stage five-year survivors by reporting institution. Survival rates 10 cases.

(per cent) are not calculated

Patients for whom the cause of dead of carcinoma of the ovary.

and the

number of

on samples containing

for

ovarian

three

and

less

than

death was unknown have been registered

as

258

OVARY

TABLE

C.Xa

Obviously malignant cases of carcinoma of the ovary. Stages I-IV (all histological classes) examined in the years 1982-1986.3 and S-year actuarial survival rate.In, formation is also given about numbers of survivors and deaths of carcinoma of the ovary as well as cases lost sight of and cases not treated.

Institution name of institution is given in List of Collaborators

Full

Years reported

Stages No. treated

I

- IV Survivors

3-year

S-year

No.

No.

Argentine

1982-86

61

34

34

Melbourne, MacCallum Carlton, Royal Women's Camperdown, R.P.A.

1984-86 1984-86 1982-86

120 79 202

49

33 82

46 30 69

Gras Innsbruck Vienna, I. Frauenklinik Vienna, II.Frauenklinik

1982-86 1982-85 1984-86 1982-86

167 91 148 85

80 33 89 27

60 27 78 22

Louvain

1984-86

79

46

39

Sao Paul0

1982-86

87

23

21

Sofia

1984-86

54

30

22

Halifax Montreal, Centre d'0nc. Montreal, HBtel Dieu Montreal, Royal Victoria Ont Ca Found., Kingston Ont Ca Found., Windsor Regina Toronto Vancouver

1984-86 1984-86 1982-86 1982-86 1982-86 1984-86 1984-86 1984-86 1984-86

142 113 62 87 125 36 191 393 368

60 59 33 40 61 16 99 21% 216

54 52 28 32 53 12 73 190 187

1.

Buenos Aires

Australia

3. 4. 6. Austria

7. 8. 9a. 10.

Belgium

11. Brasil

13.

Bulgaria

14. Canada

15. 16. 17. 18. 19. 20. 22. 23. 24.

OVARY

Stages

I-IV

No. of deaths ovarian ca. 3-yr 5-yr

Lost sight of S-year No. %

Actuarial 3-year %

survival S-year %

Total no. not treated

24

24

2

3.3

60.3

60.3

0

66 41 111

69 44 122

0 5 4

6.3 2.0

42.2 45.0 42.4

38.3 40.3 35.9

0 0 3

76 55 51 26

93 62 61 31

6 1 2 30

3.6 1.1 1.4 35.3

so.7 36.3* 61.8 62.7

37.4 26.7* 51.3 47.2

10 0 0 0

32

39

1

1.3

60.0

45.8

0

39

41

25

28.7

47.0

41.8

0

24

32

0

55.6

37.7

0

67 40 25 46 53 16 83 170 133

73 47 30 53 50 19 104 196 157

13 13 1 1 3 1 3 1 5

50.9 59.7 57.1 44.6 54.1 56.8 54.6 56.7 62.3

43.8 44.5 47.9 35.3 46.8 39.8 36.9 46.1 52.0

2 0 1 4 3 0 3 0 1

>k Crude survival

rate

9.2 11.5 1.6 1.1 2.4 2.8 1.6 0.3 1.4

259

260

OVARY

TABLE

Obviously malignant cases of carcinoma of the ovary. Stages I-IV (all histological classes) examined in the years 1982-1986 3 and 5-year actuarial survival rate. Information is also given about numbers of survivors and deaths of carcinoma of the ovary as well as cases lost sight of and cases not treated.

C.Xa

Institution Full

name of institution in List of Collaborators

Years reported

is given

Stages No. treated

I

- IV Survivors

3-year

5-year

No.

No.

Chile

25. 26.

Santiago,P.Jaraquemada Santiago,S.Juan de Dios

1982-86 1982-86

39 30

19 20

18 20

Brno, VUKEO Brno, UJEP

1982-86 1982-86

189 47

99

78 24

Helsinki Turku

1984-85 1984-86

109 40

66 20

Angers Bordeaux Caen Grenoble Lille Nice Rennes

1982,83,86 1982-86 1984-86 1982-86 1982-86 1984 1984-86

60 97 122 37 81 9 111

25 44 43 . 23 19 2 45

18 40 35 22 15 2 37

1982-86 1982-86 1982-86 1984-86 1984-86 1982-86 1985-86 1983-86 1984-86 1982-86 1982-86

105 226 45 260 41 247 67 59 82 178 127

72 96 13 134 16 91 25 37 32 88 36

65 75 12 105 15 67 23 25 29 82 32

Czechoslovakia

28. 29.

25

Finland

31. 32.

59

16

France

33. 34. 35. 37. 38. 40. 41. German

43. 46. 47. 48. 49. 50. 52. 53. 54. 55. 57.

Federal

Berlin Freiburg Fulda Giessen Greifswald Gijttingen Hannover Heidelberg Jena Kiel Leipzig

Republic

OVARY

Stages

I-IV

No. of deaths ovarian ca.

Lost sight S-year

of

3-yr

5-yr

No.

%

%

%

16 10

17 10

2 0

5.1

58.7 60.6

55.5 60.6

0 3

90 20

111 21

0 2

52.0 57.0

39.2 54.2

0 0

37 16

43 20

1 1

64.9 55,s

56.1 40.8

0 0

31 52 76 8 62 7 66

38 56 84 9 66 7 74

2 1 0 6 0 0 0

42.7 45.4 36.5 66.1 20.2

27.9 41.1 24.0 54.1 15.7

39.0

29.3

5 0 0 1 16 0 0

31 123 31 115 17 141 42 22 46 84 86

37 143 32 142 18 163 44 34 49 90 90

1 1 0 1 7 5 0 0 0 4 1

68.7 44.1 32.5 54.5 52.4 39.8 36.8 62.7 40.5 49.8 29.7

59.9 33.6 29.8 42.9 48.0 28.0 33.6 40.3 35.6 45.2 25.8

0 3 2 2 2 4 1 0 2 8 4

4.3 0.9 2,s

3.3 1.0 16.2

1.0 0.4 0.4 17.1 2.0

2.2 0.8

Actuarial 3-year

survival S-year

Total no. not treated

261

262

OVARY

TABLE

C.Xa

Obviously malignant cases of carcinoma of the ovary. Stages I-IV (all histological classes) examined in the years 1982-1986 3 and 5-year actuarial survival rate. Information is also given about numbers of survivors and deaths of carcinoma of the ovary as well as cases lost sight of and cases not treated.

Institution Full name of institution is given in List of Collaborators

58. 59. 60. 61.

Years reported

Stages No. treated

I

-

IV

Survivors 3-year No.

5-year No.

Munich, I. Frauenklinik Munich, Grosshadern Restock Wiirzburg

1982-86 1984-86 1982-86 1982-86

227 165 62 93

85 70 28 29

68 56 24 24

Athens

1982-84

100

51

36

1984-86

9

4

4

1982-86

153

93

91

Greece

62.

Hong Kong

63.

Shatin

Hungary 65. Debrecen Israel

67. 68.

Kfar Saba Tel Hashomer

1982-86

1984-86

18 61

8 29

7 21

Florence Padova

1982-86 1984-86

101 62

39

34

33 28

Kumamoto Nagasaki Okayama Tokyo

1982-86 1984-86 1984-86 1984-86

31 31 30 47

18 11 16 28

15 11 14 27

Seoul

1984-85

25

9

8

1984-86 1982-86

72 123

38 51

33 48

Italy

70. 71. Japan

73. 74. 75. 77. Korea

78.

TheNetherlands 79.

81.

Amsterdam,Acad Med Cent Groningen

OVARY

Stages I-IV No. of deaths ovarian ca.

Lost sight 5-year

3-yr

5-yr

No.

%

%

%

128 85 32 59

145 99 36 64

9 10 2 1

4.0 6.1 3.2 1.1

41.9 46.5 45.0 33.8

32.5 33.1 38.2 28.1

0 0 3 3

41

55

6

6.0

56.0

40.4

0

4

4

1

24

26

33

10 30

11 37

0 0

55 26

60 32

4 0

13 19 14 17

16 19 14 18

0 1 0 0

4

5

12

32 67

37 70

1 4

of

Actuarial 3-year

survival 5-year

Total no. not treated

0 21.6

70.4

66.4

3

44.4 49.8

37.6 36.2

0 0

43.3 57.4

36.8 45.9

0 0

58.1 38.7 52.6 57.4

47.8 38.7 52.6 54.4

0 0 0 0

48.0

86.7

65.0

0

1.4 3.3

52.1 43.0

43.5 38.9

3 0

4.0

3.2

263

264

OVARY

TABLE

C.Xa

Obviously malignant cases of carcinoma Stages I-IV (all histological classes) years 1982-1986 3 and 5-year actuarial Information is also given about numbers and deaths of carcinoma of the ovary lost sight of and cases not treated.

Institution

Years reported

Full name of institution is given in List of Collaborators 82. 83.

Stages No . treated

I

of the ovary. examined in the survival rate. of survivors as well as cases

-

IV

Survivors 3-year

5-year

No.

No.

Rotterdam Tilburg

1984-86 1984-86

98 51

48 34

43 31

Oslo

1984-86

815

423

397

Beijing, Gen Hosp of PLA 1982-86 Shanghai, Int Peace Mat 1984-86 Wuhan, Tongji Hosp 1982-86

21 33 60

8 27 36

7 26 36

Norway 85.

Peoples 87. 90. 91a.

Republic

of

China

Poland 94.

Warsaw

1982-86

385

217

196

Barcelona,H Clin y Prov Barcelona,H San Juan Barcelona, Inst Dexeus Granada Madrid, "12 de Octubre" Madrid, "La Paz"

1984-86 1984 1982-86 1982-86 1982-86 1982-86

48 4 35 73 70 110

24 3 15 35 50 60

21 1 14 33 48 56

1982-86 1982-86 1984-86

500 738 195

222 366 103

180 321 89

1982-86 1983-86 1982-86

68 24 103

26 6 45

22 5 39

1984-86

112

49

41

Spain 101. 102. 103. 104. 105. 106.

107. Gothenburg 108a.Stockholm 110. ijrebro Switzerland 111. 112. 114.

Base1 Bern Zurich

Republic 115.

of

South

Observatory

Africa

OVARY

Stages

I-IV of

Actuarial 3-year

survival 5-year

No. of deaths ovarian ca.

Lost sight 5-year

3-yr

5-yr

No.

%

%

%

50 12

55 15

0 3

5.9

50.0 75.5

42.6 65.8

0 0

373

397

4

0.5

52.1

47.0

1

13 4 21

14 5 21

0 2 2

6.1 3.3

37.4 85.3 60.0

31.7 82.0 60.0

0 1

159

180

9

2.3

55.3

48.3

1

10 1 8 35 16 42

13 2 9 37 18 45

12 0 9 3 4 7

25.0

75.7

67.5

25.7 4.1 5.7 6.4

68.4 49.0 74.2 61.1

63.1 45.9 70.1 57.8

272 352 85

306 392 96

0 4 0

0.5

45.4 51.7 55.6

37.5 45.7 47.8

0 1 0

40 17 55

44 18 61

0 0 0

39.7 27.6 45.8

33.5 22.6 39 ..2

1 0 0

47

55

13

55.1

42.2

1

11.6

Total no. not treated

265

266

OVARY

TABLE

C.Xa

Obviously malignant cases of carcinoma of the ovary. Stages I-IV (all histological classes) examined in the years 1982-1986.3 and 5-year actuarial survival rate. Information is also given about numbers of survivors and deaths of carcinoma of the ovary as well as cases lost sight of and cases not treated.

Institution Full name of institution is given in List of Collaborators

Years reported

Stages No . treated

I

- IV Survivors

3-year

5-year

No.

No.

UnitedKingdom

118. Edinburgh 120. London, Royal Marsden United

126. 128. 129. 131. 133. 134. 135. 137. 139. 140. 141. 142. 143.

States

1984-86 1984-86

225 142

80 58

70 47

1984-86 1984-86 1984-86 1984-86 1984-86 1984-86 1984-86 1984-86 1982-86 1982-86 1984-86 1984-86 1984-86

129 87 35 44 65 52 14 105 56 84 28 95 125

66 42 15 26 38 31 8 68 25 27 5 43 67

55 40 10 21 32 29 7 62 20 19 4 39 61

1982-86 1984-86

232 68

84 25

71 22

of America

Atlanta Boston, Mass Gen Hosp Charleston Chicago, Rush Med Evanston & Maywood Galveston Los Angeles, S Calif C Minneapolis NY Brooklyn, State Univ NY Stony Brook Philadelphia, Hahnemann Philadelphia, Univ Penn Winston-Salem

Yugoslavia

146. Ljubljana 147. Zagreb

OVARY

Stages

I-IV

No. of deaths ovarian ca.

Lost sight 5-year

of

3-yr

5-yr

No.

%

%

%

143 46

153 56

0 35

24.6

36.4 57.3

31.1 43.5

0 3

58 38 19 14 25 21 6 35 29 44 20 42 52

68 40 24 19 30 23 7 40 34 52 21 46 58

5 3 1 2 0 0 0 1 1 12 3 8 5

0.9 1.8 14.3 10.7 8.4 4.0

53.6 54.7 39.6 67.9 57.9 55.0 56.3 66.5 46.4 44.3 24.3 55.3 50.5

43.4 51.6 24.9 49.2 46.6 46.2 45.0 61.0 35.3 30.7 18.2 50.3 39.7

0 0 4 0 2 3 0 0 0 0 0 0 4

145 42

158 44

0 1

1.5

36.8 37.4

30.3 33.5

4 0

3.9 3.4 2.9 4.5

Actuarial 3-year

survival 5-year

Total no. not treated

267

268

OVARY

TABLE

C.Xb

Obviously malignant cases of carcinoma of the ovary (all histological classes) examined in the years 19821986. Distribution by stage and number of 3 and 5-year survivors.

Institution Full name of institution is given in List of Collaborators

Stage Ia

Stage Ib

No. alive at exam 3-yr 5-yr

No.

No. No. alive at exam 3-yr 5-yr

Argentine

1.

Buenos Aires

19

18

18

2

2

2

Melbourne,MacCallum 12 Carlton, Royal Women's 10 Camperdown, R.P.A. 32

9 9 26

9 9 26

3 0 2

2

2

2

2

Graz Innsbruck Vienna,I.Frauenklinik Vienna,II.Frauenklinik

22 9 24 5

20 8 24 1

19 8 24 1

5 6 8 7

4 4 7 3

Louvain

10

9

9

3

3

2

Sao Paul0

12

9

9

4

2

1

4

4

4

3

3

3

33 16 7 15 34 7 30 73 47

23 13 6 13 28 5 25 65 42

22 12 5 12 26 5 24 64 41

4 2 1 0 3 1 2 11 9

4 1 1

3 1 1

3 0 2 9 9

4

4

4

1

0

Australia

3. 4. 6. Austria

7. 8. 9a. 10.

Belgium

11. Brasil

13.

Bulgaria

14.

Sofia

15. 16. 17. 18. 19. 20. 22. 23. 24.

Halifax Montreal,Centre d'0nc. Montral, Hate1 Dieu Montreal,R. Victoria Ont Ca Found, Kingston Ont Ca Found, Windsor Regina Toronto Vancouver

Chile

25.

Santiago,P.Jaraqoema.

0

OVARY

Stage Ic

Stage II

No. alive at No. exam 3-yr 5-yr

Stage III

No. No. alive at exam 3-yr 5-yr

269

Stage IV

No. No. alive at exam 3-yr 5-yr

No. No. alive at exam 3-yr 5-yr

2

1

1

3

3

3

26

9

9

9

1

1

5 10 22

5 8 18

5 8 15

13 8 21

8 6 13

7 5 9

71 34 90

23 7 17

21 6 14

16 17 35

2 3 6

2 2 3

20 2 11 9

15 1 9 5

10 1 7 5

9 17 9 11

6 7 6 4

4 7 6 3

88 40 81 45

30 13 39 13

23 7 30 9

23 17 15 7

5 0 4 1

7

5

5

10

7

7

44

22

16

5

0

0

8

2

2

52

10

9

11

0

0 1

0 3

3

2

4

3

2

37

16

10

3

1

6 12 3 0 9 0 14 5 32

3 10 2

3 10 2

6

6

12 6 4 0 8

10 5 4 0 7

13 5 25

13 4 24

17 10 4 1 10 0 18 92 84

13 69 66

11 61 56

60 68 38 54 59 26 85 186 158

15 29 18 17 14 10 29 66 62

13 24 15 12 10 6 16 50 49

20 5 9 12 10 2 25 26 37

3 0 2 5 2 1 4 4 12

10

6

6

14

7

7

7

2

1

3

0

0

270

OVARY

TABLE

Obviously malignant cases of carcinoma of the ovary (all histological classes) examined in the years 19821986. Distribution by stage and number of 3 and 5-year survivors.

C.Xb

Institution

Stage Ia

Full name of institution is given in List of Collaborators

26.

Santiago,S.Juan

Stage Ib

No. alive at exam 3-yr 5-yr

No.

No. No. alive at exam 3-yr 5-yr

7

7

7

3

3

3

Brno, VUKEO Brno, UJEP

20 62

18 11

15 11

5 2

5 2

5 2

Helsinki Turku

32 5

27 4

27 3

3 1

3 1

2 1

Angers Bordeaux Caen Grer.oble Lille Nice Rennes

10 6 4 7 3 0 8

9 6 4 5 2

8 6 2 5 2

2 4

2 3

7

7

4

3

25 21 4 39 8 12 10 10 5 34 17 22 13 13 12

23 20 3 31 5 8 8 10 4 30 12 15 11 11 9

23 20 3 27 5 8 8 10 4 30 11 14 9 11 9

Czechoslovakia

28. 29. Finland

31. 32. France

33. 34. 35. 37. 38. 40. 41.

German

43. 46. 47. 48. 49. 50. 52. 53. 54. 55. 57. 58. 59. 60. 61.

Federal

Republic

Berlin Freiburg Fulda Giessen Greifswald Giittingen Hannover Heidelberg Jena Kiel Leipzig Munich,I.Frauenklinik Munich,Grosshadern Restock Wiirzburg

6 1 2 4 1 3 1 1 0 16 2 9 1 1 6

5 1 1 3 1 2 1 0 13 1 5 1 1 5

13 1 5 1 1 4

OVARY

Stage No.

exam

Ic

Stage

No. alive at 3-yr 5-yr

alive

II

Stage

No.

No.

exam

3-yr

at 5-yr

III

271

Stage

IV alive

No.

No.

No.

3-yr

at 5-yr

No.

exam

exam

3-yr

at 5-yr

alive

5

5

5

2

2

2

8

3

3

5

0

0

11 2

6 1

5 1

26 6

16 5

15 4

108 20

48 5

35 5

18 5

6 1

3 1

6 1

3 1

2 1

16 7

11 5

11 5

46 11

21 5

16 4

6 14

1 3

1 1

2 3 6 4 4 0 11

1 2 6 4 3

1 2 6 4 3

6

5

7 14 10 5 7 1 11

1 9 7 3 4 1 6

1 8 7 3 3 1 6

19 53 78 12 44 5 54

7 22 20 8 9 1 19

5 19 15 7 6 1 14

22 18 20 9 23 3 23

7 2 2 3 1 0 3

3 2 2 3 1 0 2

12 7 3 49 0 7 3 5 11 17 3 27 20 9 3

11 6 2 40

11 5 2 32

4 2 5 8 12 3 19 16 6 1

2 2 5 7 10 3 16 13 6 1

24 27 5 51 3 38 10 9 10 20 11 47 14 2 8

11 22 2 30 1 25 7 9 6 15 8 24 7 0 3

8 19 1 23 1 20 6 7 5 14 7 19 3 0 3

28 124 22 91 15 133 33 18 42 49 79 85 95 29 36

18 39 4 24 5 45 7 10 12 14 10 19 32 9 10

15 25 4 18 5 29 6 3 11 13 8 13 27 6 6

10 46 9 26 14 53 10 16 14 41 15 37 22 8 28

3 8 1 5 4 7 0 3 2 3 2 3 3 1 1

3 5 1 2 3 6 0 0 2 1 2 1 3 0 1

272

OVARY

TABLE

Obviously malignant cases of carcinoma of the ovary (all histological classes) examined in the years 19821986. Distribution by stage and number of 3 and 5-year survivors.

C.W

Stage Ia

Institution Full name of institution is given in List of Collaborators

Stage Ib

No. alive at exam 3-yr 5-yr

No.

No. No. alive at exam 3-yr 5-yr

Greece

62.

Athens

12

11

9

7

6

5

Hong Kong

63.

Shatin

0

Hungary 65. Debrecen

19

0 16

16

4

4

4

Israel

67. 68.

Kfar Saba Tel Hashomer

0 6

6

4

0 1

1

1

Florence Padova

9 6

3 5

3 5

5 1

3 1

2 1

Kumamoto Nagasaki Okayama Tokyo

7 5 8 9

7 4 8 8

7 4 7 8

0 0 1 0

1

1

Seoul

2

2

1

1

1

1

Amsterdam,Acad Med C 12 Groningen 15 Rotterdam 7 Tilburg 11

11 14 5 9

11 14 5 9

1 1 3 1

1 1 3 0

1 1 3 0

199

175

173

37

30

29

3

3

3

0

Italy

70. 71. Japan

73, 74. 75. 77. Korea

78.

Tbe Netherlands 79.

81. 82. 83. Norway

85.

Oslo

Peoples

87.

Republic

Beijing,

of

China

G H of PLA

OVARY

Stage Ic

Stage II

No. No. alive at exam 3-yr 5-yr

Stage III

No. No. alive at exam 3-yr 5-yr

273

Stage IV

No. No. alive at exam 3-yr 5-yr

No. No. alive at exam 3-yr 5-yr

17

15

10

6

5

3

43

13

9

15

2

2

2

3

2

2

4

0

0

0

12

9

9

19

12

12

53

31

30

1 0

1

1

1 8

1 8

1 7

15 34

6 12

6 8

4 8

4 8

8 11

4 8

4 7

72 30

4 6 0 10

3 4

3 4

8

8

3 3 2 9

3 1 1 5

1 1 1 5

8

2

2

7

3

4 10 13 14

4 8 9 12

4 8 8 10

13 10 15 10

45

29

29

1

1

1

1

0

46

21

20

5 8

1 10

0 1

0 1

24 11

19 7

1 6

1 1

1 0

12 10 17 18

4 0 6 7

3 0 5 6

5 7 2 1

1 2 0 0

3

4

1

1

3

0

11 8 11 6

9 6 10 5

38 65 45 14

11 18 18 7

8 17 15 7

4 21 15 1

0 2 2 0

92

65

61

321

115

99

121

9

6

2

1

1

10

-?

2

5

0

0

0

274

OVARY

TABLE

Obviously malignant cases of carcinoma of the ovary (all histological classes) examined in the years 19821986. Distribution by stage and number of 3 and 5-year survivors.

C.Xb

Institution

Stage Ia

Full name of institution is given in List of Collaborators

90. Shanghai,Int Peace 91a. Wuhan, Tongji Hosp

No. exam

Stage Ib

No. alive at 3-yr 5-yr

No. No. alive at exam 3-vr 5-yr

2 9

2 9

2 9

4 0

4

4

71

60

58

10

5

5

101. Barcelona,H Clin y Pr 102. Barcelona,H San Juan 103. Barcelona,Inst Dexeus

9 0 5

4

4

4

4

105. Madrid,"12 104. Granada de Octubre" 106. Madrid; "La Paz" SWeden

1: 24

4 4 14 20

4 4 14 20

5 0 0 2 3 2

1 2 2

1 2 2

67 181 59

57 157 54

53 150 51

14 45 11

13 38 10

11 36 9

3 2 19

3 2 16

3 2 15

0 0 3

3

27

22

21

8

5

31 14

27 13

27 13

9 1

5 1

21 18 6 7 11

17 14 3 6 11

16 14 1 6 11

3 3 0 0 3

2 3

Poland 94.

Warsaw

Spain

107. Gothenburg 108a.Stockholm 110. ijrebro Switzerland

111. Base1 112. Bern 114. Zurich Republic

of

South

Africa

115. Observatory United

Kingdom

118. Edinburgh 120. London,Royal Marsden United

126. 128. 129. 131. 133.

States

of America

Atlanta Boston,Mass Gen Hosp Charleston Chicago, Rush Med Evanston & Maywood

3

OVARY

Stage

Ic

Stage

No. exam

No. alive at 3-yr 5-yr

4 1 14 4 5 0 12 3

4 1 13 4 3

4 0 13 4 3

9 2

8

26 4

20 3

II

Stage

No. exam

No. alive at 3-yr 5-yr

2

4 1 16 3 3 2 2 14

3 0 13 1 1 1 1 9

3 0 12 1 1 1 1 9

17 3

31 7

19 3

16 3

No. exam

III

277

Stage

No. alive at 3-yr 5-yr

No. exam

16 5 45 29 49 12 54 69

10 3 20 12 14 3 22 32

9 3 16 7 6 2 19 27

16 2 10 12 14 11 16 13

102 37

23 11

19 9

57 11

IV

No. alive at 3-yr 5-yr

7 0

4 0